Kura Oncology

KURA · NASDAQ

$9.98+$0.62 (+6.62%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $9.36

Latest news

Press releaseOct 13, 7:30 AM ETGlobe Newswire
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
Press releaseSep 29, 5:15 AM ETGlobe Newswire
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
NewsSep 17, 6:34 AM ET
Kura Oncology Q2 2026 Earnings Call Transcript
NewsSep 9, 9:57 AM ETVandana Singh
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
Press releaseSep 9, 7:00 AM ETGlobe Newswire
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
Press releaseSep 8, 7:00 AM ETGlobe Newswire
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
NewsAug 25, 8:06 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsAug 25, 5:25 AM ETAvi Kapoor
Why Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Press releaseAug 12, 4:02 PM ETGlobe Newswire
Kura Oncology Reports Second Quarter 2026 Financial Results
Press releaseAug 10, 8:32 AM ETGlobe Newswire
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity
Press releaseJul 27, 6:32 AM ETGlobe Newswire
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
Press releaseJul 14, 7:02 AM ETGlobe Newswire
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
NewsJul 2, 2:08 AM ET
Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript
Press releaseJun 11, 8:02 AM ETGlobe Newswire
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Press releaseJun 3, 6:53 AM ETGlobe Newswire
Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
Press releaseJun 2, 8:32 AM ETGlobe Newswire
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
Press releaseMay 26, 6:02 AM ETGlobe Newswire
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
NewsMay 13, 8:02 AM ETAvi Kapoor
QuickLogic Posts Downbeat Q1 Results, Joins Resideo Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Press releaseMay 12, 4:02 PM ETGlobe Newswire
Kura Oncology Reports First Quarter 2026 Financial Results
Press releaseMay 12, 9:40 AM ETGlobe Newswire
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
NewsMay 12, 7:11 AM ET
Earnings Scheduled For May 12, 2026
Press releaseApr 24, 8:00 AM ETGlobe Newswire
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
NewsApr 17, 10:39 AM ETVandana Singh
Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results
Press releaseApr 17, 6:00 AM ETGlobe Newswire
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
Press releaseApr 9, 7:30 AM ETGlobe Newswire
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
NewsMar 5, 6:37 AM ET
Kura Oncology Q4 Earnings Summary & Key Takeaways
Press releaseMar 5, 6:31 AM ETGlobe Newswire
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
NewsMar 5, 6:11 AM ET
Earnings Scheduled For March 5, 2026
NewsMar 4, 1:01 PM ET
A Glimpse of Kura Oncology's Earnings Potential
Press releaseJan 11, 5:00 PM ETGlobe Newswire
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
Press releaseDec 8, 10:30 AM ETGlobe Newswire
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
Press releaseDec 4, 12:20 PM ETPRNewswire
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Press releaseNov 25, 5:16 PM ETGlobe Newswire
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
Press releaseNov 13, 10:51 AM ETGlobe Newswire
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
Press releaseNov 4, 6:31 AM ETGlobe Newswire
Kura Oncology Reports Third Quarter 2025 Financial Results
NewsNov 4, 6:12 AM ET
Earnings Scheduled For November 4, 2025
Press releaseNov 3, 4:02 PM ETGlobe Newswire
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
NewsSep 4, 3:17 PM ETVandana Singh
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth
NewsSep 4, 10:14 AM ETAvi Kapoor
This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
NewsAug 15, 10:14 AM ETAvi Kapoor
Evolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes

Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

Kura Oncology Q2 2026 Earnings Call Transcript

Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket

Kura Oncology Reports Second Quarter 2026 Financial Results

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

QuickLogic Posts Downbeat Q1 Results, Joins Resideo Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Earnings Scheduled For May 12, 2026

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

Kura Oncology Q4 Earnings Summary & Key Takeaways

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

Earnings Scheduled For March 5, 2026

A Glimpse of Kura Oncology's Earnings Potential

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Kura Oncology Reports Third Quarter 2025 Financial Results

Earnings Scheduled For November 4, 2025

Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin

Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth

This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Evolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday